NCT01573156终止1 期
Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Volume of tumour necrosis on final histology expressed as a percentage of pre-treatment tumour volume
研究概览
简要总结
Vascular Targeted Photodynamic therapy (VTP) with the Vascular Occluding Agent (VOA) WST11, may offer an alternative, providing tumour destruction via a minimally invasive approach. In this investigation, the investigators plan to use the WST11 VTP procedure to treat a predetermined small renal tumour targets. Patients will be given a general anaesthetic, to ensure immobility, and prevent discomfort during treatment sessions. Treated patients will then undergo surgical resection of their tumours, and the accuracy and reliability of tissue death with VTP will be assessed histologically. The aim of this proof of concept study is to demonstrate whether this modality has potential for a clinical role in the treatment of oncological kidney disease, either as an alternative to surgery, or where surgery is not feasible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is willing and able to give informed consent for participation in the study.
- •Male or post-menopausal female, aged 60 years or above.
- •Lesions suspicious for renal cell carcinoma on triple phase CT that are < 4cm in maximum diameter and suitable for surgical resection
- •Participant must be in sufficiently good health to be suitable for general anaesthesia for both VTP treatment and subsequent surgical resection of tumour
- •Subjects must have ≥ 1 evaluable tumours which can be visualized on diagnostic ultrasound. If more than one tumour exists, an index tumour will be nominated and treated (uncommon)
- •Previous chemotherapy and / or biological therapy for cancer are permitted, but the subject should have recovered fully from the effects of these and any prior surgery (minimum of 28 days).
- •Patients should not have received radiotherapy to the target area within the preceding 12 months.
- •Subject has clinically acceptable haematological, electrolyte and hepatic function as demonstrated by serum laboratory values within 14 days prior of VTP treatment:
- •Absolute neutrophil count (ANC) ≥ 1500mm-3
- •Platelet count ≥ 100,000mm-3
- •Haemoglobin ≥ 10gdl-1
- •Prothrombin time (PT) ≤ 1.5 * Upper Limit of Normal (ULN)
- •Activated partial thromboplastin time (APPT) ≤ 1.5 * ULN
- •Total bilirubin < 2.5 * ULN
- •Aspartate aminotransferase (AST) < 3 * ULN
- •Alkaline phosphatase (ALP) < 2 * ULN; unless arising from bone
- •Participants has a clinically acceptable ECG
- •Able (in the Investigators opinion) and willing to comply with all study requirements.
- •Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
排除标准
- •The participant may not enter the study if ANY of the following apply:
- •Non menopausal women
- •Significant hepatic impairment.
- •Significant renal impairment as to mean surgical resection is unsuitable
- •Clinical or radiological evidence of metastatic disease
- •Subjects with tumours lying adjacent to vital structures such that VTP treatment would risk damage to these structures
- •Subjects currently taking immunosuppressive medication
- •Patients whose medical conditions need the following medication which have potential photosensitizing effects (tetracyclines, sulphonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin and amiodarone (see appendix G)) if these treatments cannot be stopped or replaced by other treatments without photosensitizing properties
- •Patients who have an absolute need for anticoagulant drugs or antiplatelet drugs (e.g., warfarin, aspirin), which cannot be withdrawn during the 10 days prior to the VTP procedure.
- •Scheduled elective surgery or other procedures requiring general anaesthesia during the study.
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- •Participants involved in the treatment phase of a clinical trial (observational or follow-up studies will be allowed)
- •An American Society of Anaesthesiologists (ASA) score of ≥ 3
- •A World Health Organization (WHO) performance status of ≥2
研究组 & 干预措施
VTP treatment to small renal mass
Experimental
干预措施: Light activated WST11 (Drug)
结局指标
主要结局
Volume of tumour necrosis on final histology expressed as a percentage of pre-treatment tumour volume
时间窗: 2-4 weeks post VTP therapy
次要结局
- Radiological evidence of tissue destruction at day 12 (technical success) based on the volume of tumour ablation on day 12 MRI imaging expressed as a percentage of pre-treatment tumour volume(12 days post VTP therapy)
- Adverse events according to Common Toxicity Criteria (CTCAE)(Up to 12 months post VTP)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
ight activated drug treatment for small kidney tumoursT1a renal cancerMedDRA version: 15.0 Level: PT Classification code 10038391 Term: Renal cancer stage I System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003311-27-GBniversity of Oxford5
进行中（未招募）
不适用
Vascular-targeted photodynamic therapy using WST11 in patients with localised prostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2008-000876-26-NLSTEBA BIOTECH N.V.24
进行中（未招募）
不适用
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCEEUCTR2008-000876-26-FRSTEBA BIOTECH NV24
进行中（未招募）
不适用
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCERocalized prostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2009-012809-19-NLSTEBA BIOTECH SA30
进行中（未招募）
1 期
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCERocalized prostate cancerMedDRA version: 9.1 Level: LLT Classification code 10060862 Term: Prostate cancerEUCTR2009-012809-19-GBSTEBA BIOTECH SA30